Literature DB >> 29939164

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis.

Hui-Ching Hsu1, Ming-Feng Liao2, Jung-Lung Hsu2, Yun-Lin Lee2, Long-Sun Ro3.   

Abstract

Genetic testing is the most reliable test for hereditary transthyretin related amyloidosis and should be performed in most cases of transthyretin amyloidosis (ATTR). ATTR is a rare but fatal disease with heterogeneous phenotypes; therefore, the diagnosis is sometimes delayed. With increasing attention and broader recognition on early manifestations of ATTR as well as emerging treatments, appropriate diagnostic studies, including the transthyretin (TTR) genetic test, to confirm the types and variants of ATTR are therefore fundamental to improve the prognosis. Genetic analyses with polymerase chain reaction (PCR) methods confirm the presence of TTR point mutations much more quickly and safer than conventional methods such as southern blot. Herein, we demonstrate genetic confirmation of the ATTR Ala97Ser mutation, the most common endemic mutation in Taiwan. The protocol comprises four main steps: collecting whole blood specimen, DNA extraction, genetic analysis of all four TTR exons with PCR, and DNA sequencing.

Entities:  

Mesh:

Year:  2018        PMID: 29939164      PMCID: PMC6101697          DOI: 10.3791/57743

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  26 in total

1.  Rapid detection of wild-type and mutated transthyretins.

Authors:  Masayoshi Tasaki; Mitsuharu Ueda; Konen Obayashi; Hiroaki Motokawa; Yumiko Kinoshita; Genki Suenaga; Akihiro Yanagisawa; Risa Toyoshima; Yohei Misumi; Teruaki Masuda; Taro Yamashita; Yukio Ando
Journal:  Ann Clin Biochem       Date:  2015-09-04       Impact factor: 2.057

2.  Hereditary amyloidosis: detection of variant prealbumin genes by restriction enzyme analysis of amplified genomic DNA sequences.

Authors:  W C Nichols; M D Benson
Journal:  Clin Genet       Date:  1990-01       Impact factor: 4.438

Review 3.  One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition.

Authors:  O B Suhr; E Lundgren; P Westermark
Journal:  J Intern Med       Date:  2017-01-17       Impact factor: 8.989

4.  Detection of three transthyretin gene mutations in familial amyloidotic polyneuropathy by analysis of DNA extracted from formalin-fixed and paraffin-embedded tissues.

Authors:  Y Date; M Nakazato; K Kangawa; K Shirieda; T Fujimoto; S Matsukura
Journal:  J Neurol Sci       Date:  1997-09-10       Impact factor: 3.181

5.  Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP).

Authors:  V Planté-Bordeneuve; A Ferreira; T Lalu; C Zaros; C Lacroix; D Adams; G Said
Journal:  Neurology       Date:  2007-08-14       Impact factor: 9.910

6.  Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction.

Authors:  Jian Ye; George Coulouris; Irena Zaretskaya; Ioana Cutcutache; Steve Rozen; Thomas L Madden
Journal:  BMC Bioinformatics       Date:  2012-06-18       Impact factor: 3.169

7.  NCBI BLAST: a better web interface.

Authors:  Mark Johnson; Irena Zaretskaya; Yan Raytselis; Yuri Merezhuk; Scott McGinnis; Thomas L Madden
Journal:  Nucleic Acids Res       Date:  2008-04-24       Impact factor: 16.971

Review 8.  Recent advances in transthyretin amyloidosis therapy.

Authors:  Mitsuharu Ueda; Yukio Ando
Journal:  Transl Neurodegener       Date:  2014-09-13       Impact factor: 8.014

Review 9.  Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors.

Authors:  Alan J Fox; Matthew C Hiemenz; David B Lieberman; Shrey Sukhadia; Barnett Li; Joseph Grubb; Patrick Candrea; Karthik Ganapathy; Jianhua Zhao; David Roth; Evan Alley; Alison Loren; Jennifer J D Morrissette
Journal:  J Vis Exp       Date:  2016-09-20       Impact factor: 1.355

10.  Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese.

Authors:  Hui-Ching Hsu; Ming-Feng Liao; Jung-Lung Hsu; Ai-Lun Lo; Hung-Chou Kuo; Rong-Kuo Lyu; Victor Chien-Chia Wu; Chih-Wei Wang; Long-Sun Ro
Journal:  BMC Neurol       Date:  2017-09-07       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.